The human c-H-ras1 gene contains within the ®rst intron a p53 element, which functions as a transcriptional enhancer. Using nuclear extracts from human endometrial and ovarian tumours in gel retardation assays, we examined the binding levels of the P53 protein to the Hras element in tumour versus the adjacent normal tissue. Elevated P53 binding in the tumour tissue was found in 5/12 (42%) endometrial and in 2/5 (40%) ovarian specimens and these cases were found to overexpress wild-type P53. Loss of P53 binding to the H-ras element due to p53 mutations, was observed in 3/12 (25%) endometrial and in 1/5 (20%) ovarian cases. Similar P53 binding levels to the H-ras element were found in 4/12 (33%) endometrial and in 2/5 (40%) ovarian pairs showing normal expression of wild-type P53. Overexpression of the Ras p21 protein correlated with elevated binding and increased nuclear levels of wildtype P53. Our results suggest that P53 protein alterations, participate in the development of human gynecological neoplasias through aberrant transcriptional regulation of the H-ras proto-oncogene.
Introduction
The three mammalian ras proto-oncogenes, H-ras1, K-ras2 and N-ras, encode small GTP-binding proteins sharing 90% amino acid identity, termed p21, which are involved in multiple cytoplasmic signal transduction pathways (Marshall, 1995) . Oncogenic point mutations, at codons 12, 13 and 61 as well as overexpression of wild-type p21 are frequently observed in human and animal tumours (Lowy and Willumsen, 1993; Egan et al., 1987) .
The human H-ras1 gene has a 5' non-coding exon (exon-I), four coding exons (I-IV) and a variable tandem repeat sequence (VTR), located downstream of the polyadenylation signal (Figure 1 ). Transcriptional regulation of the H-ras gene (reviewed by Zachos and Spandidos, 1997) , includes regulation from promoter-like sequences, from intronic sequences, the VTR region, DNA methylation and alternative splicing in both the fourth intron and the 3' terminal H-ras exon (Hwang and Cohen, 1997) . The ®rst intron of the gene contains well conserved regions between human and rodents and encompasses a glucocorticoid response element and a p53 binding site. In these studies we determined that wild-type P53 speci®cally recognizes the H-ras element. We showed that the H-ras p53 element acts as a transcriptional enhancer in the presence of wild-type, but not mutant forms of the P53 protein Zoumpourlis et al., 1995) .
Inactivation of the p53 tumour-suppressor gene by mutations, viral or cellular proteins, is the most frequently observed genetic abnormality identi®ed in human tumours (Levine et al., 1991) . Loss of wild-type p53 function decreases the eciency of mutation repair, thus raising the possibility that cells with neoplastic potential will develop (Lane, 1992) . Overexpression and mutation of the p53 gene may serve as independent prognostic indicators in the development of human endometrial and ovarian neoplasias (Kihana et al., 1995; Soong et al., 1996; Levesque et al., 1995; Klemi et al., 1995) .
In the present study, we have examined the binding levels of endogenous P53 protein to the H-ras element, using nuclear extracts from human endometrial and ovarian lesions. We also examined the p53 gene status and expression levels and correlated them with Ras p21 overexpression.
Results

P53 binding levels to the H-ras gene in human endometrial and ovarian lesions
Organization of the c-H-ras1 gene and position of the H-ras p53 element are shown in Figure 1 . Twelve pairs of endometrial and ®ve pairs of ovarian tumoursadjacent normal tissues were examined for P53 binding to the H-ras element by means of gel retardation assays. We found elevated P53 binding to the H-ras element in the tumour tissue in 5/12 (42%) endometrial and 2/5 (40%) ovarian pairs tested. In 3/12 (25%) endometrial and 1/5 (20%) ovarian pairs, P53 binding to the H-ras was not detected in the tumour tissues, however tumours were positive for P53 using Western blot analysis (data not shown). In the remaining 4/12 (33%) endometrial and 2/5 (40%) ovarian pairs tested, similar P53 binding levels in tumour versus normal tissue was observed. A representative example from each category of cases is shown in Figure 2 . Regarding the ovarian tumours, two bands were observed and marked as`a' and`b'.
Using oligonucleotide competitors (data not shown) and an anti-P53 antibody, we showed that both`a' and b' bands represent a speci®c P53-DNA complex (Figure 3 ). Both Eras 2HS/P53 and control BC/P53 complexes were abolished when anti-P53 antibody was included in the reaction mixture, thus indicating the speci®city of the observed P53/DNA interaction.
Mutated forms of the P53 protein fail to bind to the H-ras element
To interpret the aberrant P53 binding to the H-ras element in the majority of tumours (either elevated, or lost in the tumour tissue), we examined all endometrial and ovarian tumour-normal tissue pairs for p53 gene mutations. We performed polymerase chain reactionsingle strand conformation polymorphism (PCR ± SSCP) analysis of exons 4 ± 9, encompassing the mutational`hot spots' of the p53 gene in human tumours (Levine et al., 1991) . Three cases of endometrial (patients 2 ± 4) and one case of ovarian (patient 1) neoplasias were found to carry a single point mutation (Figure 4 ). All four samples corresponded to cases which were negative for P53 binding to the H-ras DNA and were shown to lack the normal p53 allele by loss of heterozygosity (LOH) analysis (data not shown). Mutations were con®rmed by sequencing of the samples. Patient 1 has an exon 6, codon 220, TAT to TGT (Tyr to Cys) transition. Patient 2 has an exon 6, codon 209, AGA to ATA (Arg to Ile) transversion. Patient 3 has an exon 4, codon 87, CCA to CAA (Pro to Gln) transversion. Patient 4 has an exon 7, codon 248, CGG to CAG (Arg to Gln) transition.
Cases showing similar or elevated ras DNA binding in tumour tissue were not found to harbour mutated p53 alleles, indicating that mutated P53 forms found in human endometrial and ovarian lesions fail to bind to the H-ras element.
Elevated binding of the P53 protein to the H-ras element is due to increased levels of wild-type P53 and correlates with overexpression of the Ras p21 protein
We next performed Western blot analysis in the tumour-normal tissue pairs, to determine the levels of P-endlabelled Eras 2HS (lanes 1, 2) and BC (lanes 3, 4) probes were incubated with 40 mg of nuclear extracts from ovarian tumour tissue. P53-speci®c bands were abolished in the presence of 0.5 mg of anti-P53 antibody (lanes 2, 4) P53 and Ras p21 proteins. In the ®ve endometrial and the two ovarian tissue pairs that showed elevated P53 binding to H-ras in tumour tissue, we found increased levels of the P53 protein in tumour tissue in all pairs, suggesting that elevated P53 binding resulted from increased levels of wild-type P53 (Figure 5a ). Additionally, overexpression of the Ras p21 protein in tumour versus normal tissue was detected in all cases (Figure 5b ). Concerning the four cases of human endometrium and the two cases of human ovary that showed no dierences in P53 binding to the H-ras element in tumour versus normal tissue, we detected overexpression of the Ras p21 in two cases and in one case, respectively. No P53 overexpression was detected in these tissue pairs. Finally, elevated expression of the Ras p21 protein was detected in one case of endometrial tumour, harbouring a mutated p53 allele. Overexpression of P53 mutants was detected in all cases.
Increased levels of the Ras p21 protein are often due to mutation of a ras gene family member. Codon 12 point mutations of the H-ras and K-ras genes occur in a small subset (10 ± 15%) of endometrial carcinomas in the Greek population . We performed PCR-restriction fragment length polymorphism (RFLP) analysis, to examine whether the increased levels of the Ras p21 protein found in tumour tissues, were related to codon 12 point mutations of H-, K-or N-ras genes. We observed only one case harbouring a K-ras codon 12 mutation in an endometrial tumour tissue sample (data not shown). This case overexpressed Ras p21, and showed similar P53 binding to H-ras and normal expression levels in tumour versus normal tissue. Table 1 summarises the data presented for each sample tested.
Discussion
The H-ras proto-oncogene contains in the ®rst intron a p53 binding element that acts as a transcriptional enhancer in vitro in the presence of a wild-type P53 protein Zoumpourlis et al., 1995) .
In the present study, we report alterations in P53 binding to the H-ras element, in human endometrial and ovarian tumours. Elevated binding of the P53 protein was detected in 5/12 (42%) endometrial and in 2/5 (40%) ovarian tumours, compared to the respective normal tissue: the P53 protein was of wild-type form and overexpressed. The latter may result from upregulation of the p53 transcription levels, or from a decreased rate of Mdm2-induced degradation of the P53 protein (Kubbutat et al., 1997) .
Moreover, in 3/12 (25%) endometrial and in 1/5 (20%) ovarian cases, P53 protein from tumour tissue was unable to bind to the H-ras element and loss of P53 binding resulted from mutations of the gene. This is in agreement with our previous results, showing that in vitro translated mutant forms of the P53 protein were unable to recognize the H-ras element .
Increased levels of the Ras p21 protein were detected in over 60% of endometrial (Long et al., 1988 , Miturski et al., 1996 and in approximately 50% of ovarian tumours (Scambia et al., 1997) , and are of prognostic signi®cance. Our results show that overexpression of the Ras p21 protein in tumour Furthermore, overexpression of the Ras p21 was detected in 3/6 (50%) endometrial and ovarian tumours showing similar levels of P53 binding to the H-ras in tumour versus normal tissue and in 1/4 (25%) cases exhibiting loss of P53 binding activity in tumour tissue. H-ras contains a glucocorticoid response element in the ®rst intron and an estrogen response element in the fourth intron of the gene . In a previous study, we showed elevated steroid receptor binding to the corresponding elements of the H-ras gene in more than 90% of endometrial and ovarian tumour-normal pairs tested . It is therefore suggested that regulation of H-ras expression by steroid receptors, as well as ras genes mutations (found in one tumour sample), accounts for overexpression of Ras p21 protein in these cases.
The human endometrium and ovary are major targets for action of glucocorticoids and sex hormones. In a previous study, we proposed that endometrial and ovarian epithelial cells have a predisposition to develop neoplastic abnormalities, due to hormonally induced overexpression of the Hras gene (Zachos et al., 1996b; Zachos and Spandidos, 1997) . Correlation between Ras p21 overexpression and estrogen receptor levels in ovarian tumours was also proved (Scambia et al., 1993) , moreover, estrogens participate in regulation of the P53 levels (Hurd et al., 1997) . Furthermore, simultaneous detection of Ras p21 and P53 protein is correlated with the advanced clinical stage of human endometrial carcinomas (Miturski et al., 1996) . We suggest that steroid hormone receptors, p53 mutations and overexpression and modulation of the H-ras gene transcription levels are inter-related factors in a delicate interplay which is implicated in the development of gynecological neoplasias.
Materials and methods
Biopsy material
Endometrial and ovarian epithelial tumour and adjacent normal tissues were obtained from Alexandra Hospital, Athens, Greece. The term`normal tissue' refers to macroscopically normal endometrium and ovary, which was microscopically composed of purely benign tissue. There was no statistical correlation between the cases tested and the tumour pathological type, stage and degree of dierentiation or the age of the patients.
Nuclear and total cell extract preparation
Tissues were ®nely minced on dry ice and nuclear extracts were prepared as previously described . Total cell extracts were prepared as described (Brooks et al., 1996) and protein concentrations were measured by the method of Bradford.
Oligonucleotides and labelling
The Eras 2HS probe encompassing the c-H-ras1 p53 element was as previously described . The control BC probe, containing an optimal P53 binding site was also as described (Halazonetis et al., 1993) . MDM-2 oligonucleotide contains the p53 element of the mdm-2 gene and was used for competition experiments (Juven et al., 1993) . SP-1 was used as a P53-unrelated oligonucleotide competitor . Radioactive end labelling was performed using T4 polynucleotide kinase (Boehringer, Mannheim) and g-32 P-ATP (Maniatis et al., 1989) .
DNA binding assay
DNA binding reactions were carried out in binding buer consisting of 10 mM Tris pH 8.0, 50 mM NaCl, 0.5 mM PMSF, 5% glycerol, 0.1 mM ZnOAc, 1 mM DTT and 50 mg/ml poly(dI-dC) (Halazonetis et al., 1993) as described . The samples were electrophoresed on 4% polyacrylamide gel (acryl : bis=19 : 1) and visualized by autoradiography. For competition and antibody experiments, a 200-fold molar excess of unlabelled oligonucleotides or 0.5 mg of monoclonal anti-P53 antibody Pab421 (Ab-1, Oncogene 
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DNA extraction, PCR ± SSCP analysis, LOH, RFLP analysis, DNA sequencing
Genomic DNA was isolated from the nuclear debris prepared during extraction of nuclear proteins, following standard procedures (Maniatis et al., 1989) . Primers and PCR conditions used for polymerase chain reaction-single strand conformation polymorphism (PCR ± SSCP) analysis of exons 4 ± 9 of the p53 gene, were as previously described (Liloglou et al., 1997) . PCR products were electrophoresed on 10% polyacrylamide gels (acryl : bis=37.5 : 1), at 300 Volts for 9 ± 15 h, at 48C and visualized by silver staining. Microsatellite markers TP53 (located inside the p53 gene), D17S515, D17S578 and D17S695 (located in the vicinity of p53 gene) were used for loss of heterozygosity (LOH) analysis. PCR reactions were performed in a 50 ml reaction volume, containing 100 ng of genomic DNA, 200 mM dNTPs, 10 pmol of each forward and reverse primer, 10 mM TrisHCl, pH 8.8, 1.5 mM MgCl 2 , 50 mM KCl, 0.1% Triton X-100 and 2U Dynazyme TM II DNA polymerase (Finnzymes OY, Finland). The DNA was ampli®ed for 30 cycles, at 948C, 558C, 728C each step. PCR products were electrophoresed in a 10% polyacrylamide gel and silver stained.
PCR primers and conditions used for detection of H-, Kand N-ras codon 12 point mutations with PCR-restriction fragment length polymorphism (RFLP) analysis, were as previously described .
Cycle sequencing was performed for each selected DNA fragment in the presence of 20 mM of the primers used for PCR ± SSCP analysis, 1 ml of [a 32 P]dCTP (Amersham, 6000 Ci/mmol) and 50 ng of the template (AmpliCycle sequencing kit, Perkin-Elmer).
Western blotting
For the P53 protein, Western blotting was performed in cell nuclear extracts, using 0.5 mg (dilution 1 : 200) anti-p53 antibody Pab421 (Ab-1, Oncogene Science). For the Ras p21 protein, immunoblotting was performed in total cell extracts using 0.5 mg (dilution 1 : 200) monoclonal anti-p21 Y13-259 antibody (Furth et al., 1982) . The hY13-259 antibody is speci®c for both mutated and wild-type p21, from human H-, K-and N-ras genes. The ECL kit (Amersham) was used following the instructions of the manufacturer.
Statistical analysis
The w 2 test for signi®cance was used.
